ResMed's Enterprise Value for the quarter that ended in Dec. 2023 was $26,483 Mil.
ResMed's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $1,215 Mil. ResMed's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was 4.59%.
The historical rank and industry rank for ResMed's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
RMD'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 2.08 Med: 3.86 Max: 7.37
Current: 4.54
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of ResMed was 7.37%. The lowest was 2.08%. And the median was 3.86%.
RMD's Earnings Yield (Joel Greenblatt) % is ranked better than 72.41% of 848
companies
in the Medical Devices & Instruments industry
Industry Median: 0.19
vs RMD: 4.54
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. ResMed's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 16.95%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
ResMed Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for ResMed's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
ResMed Annual Data
Trend
Jun14
Jun15
Jun16
Jun17
Jun18
Jun19
Jun20
Jun21
Jun22
Jun23
Earnings Yield (Joel Greenblatt) %
2.98
2.82
2.51
3.20
3.44
ResMed Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Earnings Yield (Joel Greenblatt) %
3.27
3.33
3.44
5.06
4.59
Competitive Comparison
For the Medical Instruments & Supplies subindustry, ResMed's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ResMed Earnings Yield (Joel Greenblatt) % Distribution
For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where ResMed's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
ResMeds Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Jun. 2023 is calculated as
ResMed's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,215 Mil.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
ResMed Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of ResMed's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RMD has been successfully added to your 